Proteomics International Begins National Rollout Of Promarker Tests Through Healius
PIQ: $0.120 +2.13% · MC: $16M
Proteomics International has begun a national rollout of Promarker D and Promarker Eso through Healius, following their controlled release in Western Australia and the Northern Territory. It reported quarterly operating cash outflows of approximately $2 million and cash of approximately $2 million at quarter-end; a subsequent approximately $2 million research and development tax incentive lifted its pro forma cash position to approximately $4 million. Promarker Endo is expected to become commercially available in FY27 Q3, subject to clinical deployment and applicable requirements.

Comments